Smith & Nephew SNATS (NYSE:SNN) Hits New 52-Week Low – Should You Sell?

Smith & Nephew SNATS, Inc. (NYSE:SNN) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $28.93 and last traded at $28.8560, with a volume of 346336 shares trading hands. The stock had previously closed at $30.28.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Kepler Capital Markets cut shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Canaccord Genuity Group cut their price target on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. The Goldman Sachs Group reissued a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Weiss Ratings downgraded shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. Finally, Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $30.93.

Smith & Nephew SNATS Stock Performance

The business’s fifty day moving average price is $30.41 and its 200 day moving average price is $32.54. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.57 and a quick ratio of 1.25.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Garner Asset Management Corp acquired a new stake in shares of Smith & Nephew SNATS during the fourth quarter worth about $27,000. Arax Advisory Partners increased its position in Smith & Nephew SNATS by 142.6% in the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 569 shares during the period. Advisors Asset Management Inc. acquired a new position in Smith & Nephew SNATS in the 4th quarter valued at about $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in Smith & Nephew SNATS during the 3rd quarter valued at approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Smith & Nephew SNATS during the 4th quarter valued at approximately $43,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.